Level B· Emerging clinical evidence with positive signalsRandomized Controlled TrialPubMedOpen access

Hypoxia conditioned adipose-derived stem cell-derived extracellular vesicle therapy improves cardiac function in a rat model of ischemic cardiomyopathy.

Kumagai K., Kawamura T., Torigata K., Harada A., Kishimoto Y., Miyagawa S.

Randomized Controlled Trial on Cardiovascular Disease, Chronic Inflammation, published in Regen Ther (2026) — summary generated from the PubMed abstract.

Open my reading list
Level B· Emerging clinical evidence with positive signalsEvidence level of this study

Several human studies show positive signals, while research methods and sample sizes continue to develop.

  • Level A · Stronger Clinical Evidence
  • Level B · Emerging clinical evidence with positive signals
  • Level C · Early human research exploring benefits
  • Level D · Scientific groundwork from lab and animal studies
  • Emerging · Emerging topic under active research
Read the A–D evidence level guide

This page is generated from the PubMed record. The Thai description is an automated summary of bibliographic fields and the abstract, not a full translation, and is not medical advice.

Study type
Randomized Controlled Trial
Journal
Regen Ther (2026)
Country
Netherlands
Reported sample size
—
Source database
PubMed
PMID
41948478
PMCID
PMC13051720
DOI
10.1016/j.reth.2026.101105

Abstract (original English)

Extracellular vesicles (EVs) are potential cell-free therapies for cardiac regeneration. Although adipose-derived stem cells (ADSCs) are easily obtained using minimally invasive procedures, therapeutic effects of hypoxically conditioned ADSC-derived EVs on the heart remain unknown. We aimed to verify whether hypoxic preconditioning enhances the therapeutic efficacy of ADSC-derived EVs. Lewis female rats were used to isolate ADSCs and establish an ICM rat model. ADSCs were cultured in a 48-h exosome-free medium under 5% or 20% O 2 , and EVs were recovered using polyethylene glycol and ultracentrifugation. An MI model was created by ligating the left anterior descending artery via mini thoracotomy; EF<45% was confirmed 2 weeks later. Rats were randomly assigned to three groups (PBS, normoxic EV, and hypoxic EV groups), each undergoing mini thoracotomy and myocardial injection. Echocardiography was performed at 2- and 4-weeks post-administration to evaluate cardiac function, and histological analysis of fibrosis and angiogenesis was performed at 4 weeks. We performed miRNA sequencing on both EVs and RNA sequencing on the myocardium 2 days after administration. Functional analysis of EV microRNAs suggested that hypoxia increased levels of miRNAs involved in suppressing fibrosis. Echocardiography at 2 and 4 weeks post-EV administration showed greater improvement in cardiac function

What this study does not prove

  • • This study does not prove SVF is an approved treatment or a replacement for standard care.

Evidence level

Several human studies show positive signals, while research methods and sample sizes continue to develop.

How we grade evidence

Browse all related research

Filter the research library by this study's title keywords, author, or publication year.

Related research